Clinical Trials Logo
  1. Home
  2. Essential Tremor
  3. NCT05214222

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma — ANSWER  

Essential Tremor Clinical Trial

Official title:
Penpulimab Plus Chemotherapy With or Without Anlotinib as First-line Therapy for Patients With Advanced Esophageal Squamous Cell Carcinoma (Answer): A Randomized Two-arm Clinical Study

Clinical Trial Summary

Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy for patients with advanced esophageal squamous cell carcinoma (Answer): A randomized two-arm clinical study.

Clinical Trial Description

This is a open-label, phase II study of Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy in subjects With resectable advanced esophageal squamous cell carcinoma. The patients will be divided into two groups. In group A, Penpulimab plus chemotherapy with Anlotinib will be given every 3 weeks for 4-6 cycles in initial stage, then in maintenance treatment, Anlotinib and Penpulimab will be used every 3 weeks until disease progression or intolerance; In group B, Penpulimab plus chemotherapy will be given every 3 weeks for 4-6 cycles in initial stage, then in maintenance treatment, Penpulimab will be used every 3 weeks until disease progression or intolerance; ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05214222
Study type Interventional
Source Nanfang Hospital of Southern Medical University
Contact wei wang
Phone 020-61642136
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date March 1, 2022
Completion date July 1, 2024
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT05381688 - VIM DBS Respiratory Modulation: N-of-1 Trial
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Completed NCT02277106 - Evaluate SAGE-547 in Participants With Essential Tremor Phase 2
Terminated NCT02678429 - Atlas Predicted DBS Settings in Essential Tremor Phase 4
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A
Completed NCT02523807 - Tremor Monitoring Device N/A
Active, not recruiting NCT02255929 - Gamma Knife Radiosurgery for Treatment of Essential Tremor N/A
Completed NCT01223144 - Decision-making and Emotion Recognition in Essential Tremor N/A
Completed NCT00906412 - Ventrointermediate Nucleus (VIM DBS) and Working Memory N/A
Completed NCT03051178 - Wearable Sensor for Responsive DBS for ET N/A
Recruiting NCT03795935 - Relief From Side Effects: Clinical Use of Electrodes With Direction N/A
Recruiting NCT04501133 - Sensory-specific Peripheral Stimulation for Tremor Management N/A
Active, not recruiting NCT03560622 - Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy N/A
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A
Recruiting NCT05106816 - The Effects of Vibrotactile Stimulation in Patients With Movement Disorders N/A
Completed NCT05480215 - Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ Bands N/A
Recruiting NCT04720469 - A Second Magnetic Resonance Guided Focused Ultrasound Thalamotomy for Essential Tremor N/A
Completed NCT01468948 - Octanoic Acid for Essential Tremor Phase 1
Recruiting NCT04032470 - Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
Completed NCT02947841 - The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients N/A